IthaMaps

Welcome to IthaMaps

IthaMaps is a global epidemiology database of heamoglobinopathies, illustrating published data on a dynamic global to regional map. Country-specific information on haemoglobinopathy-related policies, prevalence, incidence and overall disease burden is given, including relative allele frequencies of specific globin mutations in each country and/or region, dynamically linked to corresponding IthaGenes entries.

IthaMaps content was supported by partnership with the HVP Global Globin 2020 Challenge

Search

Search Country:		OR	Search for:		Show organisations

Healthcare information:
Major haemoglobinopathies:

Mutation search

Select locus:		Select mutation:

More Fewer search options

General information for United Arab Emirates

United Arab Emirates

Continent:	Asia
Capital:	Abu Dhabi
Population:	4975593
Area (in sq km):	82880.0

Haemoglobinopathy-specific healthcare policy information for United Arab Emirates

Healthcare policy		Comment/Info	Reference
Prevention programme:	Yes (National)	Based on premarital screening. Implemented in 2011. Mandatory.	[PMID: 11773575]
SCD newborn screening:	Yes (National)	Since 2005. Voluntary.	[PMID: 29751732]
Prenatal screening:	No		[PMID: 11773575]
Antenatal screening:	Yes (National)	As part of the haemoglobinopathies prevention programme. From: 2011 WHO Report WHO-EM-NCD-068-E.
Dedicated treatment centres:	Yes (Regional)
Patient associations:	Yes (National)	E.g.: Emirates Thalassaemia Society.
Genetic counselling:	Yes (National)	As part of the prevention programme.	[PMID: 11773575]

Prevalence and incidence of major haemoglobinopathies in United Arab Emirates

Haemoglobinopathy		Comment/Info	Reference
Prevalence of β-thalassaemia carriers:	8 % of the population		[PMID: 24672827]
Prevalence of sickle cell disease carriers:	1.1 % of the population		[PMID: 24672827]
Prevalence of α-thalassaemia carriers:	49 % of the population		[PMID: 23224852]
Prevalence of Hb E carriers:	0.01 % of the population	Abu Dhabi emirate	[PMID: 16602448]
Prevalence of Hb C carriers:	0.05 % of the population		[PMID: 16602448]
Expected incidence of β-thalassaemia:	123 expected affected births/year		[PMID: 24672827]
Expected incidence of sickle cell disease:	36 expected affected births/year		[PMID: 24672827]
Incidence of sickle cell disease:	4 affected births/year	Median value estimated using statistical model and demographic data.	[PMID: 23103089]
Known β-thalassaemia patients:	1000 patients		[PMID: 24672827]

Global Burden of Disease data for United Arab Emirates

Migration data for United Arab Emirates

Mutation frequencies in United Arab Emirates

Overview (most frequent mutations with their observed average values and range)

β-locus

IVS I-5 (G>C): 59.5 % (53 % – 66 %)	IVS I [3' end] (-25 bp): 7.4 % (6.8 % – 8 %)
CD 8/9 (+G): 5.4 % (2.8 % – 8 %)	CD 5 -CT: 3.8 % (1.6 % – 6 %)

Detailed mutation frequencies

	Entry ID	Locus	Region	Ethnic Group	Population Type	Sample Size	Study period (from)	Study period (to)	Reference	Comments
	21464	β-locus	Dubai	Emirati	Patients	376	1995	2007	22074124	Frequencies are shown for beta-globin gene mutations. Study samples were acquired from the Dubai Genetic and Thalassemia Center.
	21465	β-locus	Country-wide	Emirati	Carriers	50		1994	8151640	Frequencies are shown for beta-globin gene mutations. Study samples were acquired from the genetic clinic of Al-Jimi and Tawam Hospital (Al-Ain), and were mainly from Al-Ain District, Sharjah, and Ras al-Khaimah.

Organisations in United Arab Emirates

A list of all organisations in United Arab Emirates stored in the ITHANET database is shown below. For more information, click on the corresponding organisation name or visit the detailed ITHANET Organisations page

Name	Department	Organisation type
Canadian Hospital United Arab Emirates (CSH)		Research Center, Medical Center, Diagnostic Center
Dubai Medical College (DMC)	Genetic &Thalassemia	Research Center, Medical Center, Higher Education, Diagnostic Center
Latifa Hospital	Clinical Psychology	Medical Center, Diagnostic Center
Sheikh Khalifa Medical City (SKMC)	Pediatric Hematology & Oncology	Medical Center, Diagnostic Center

Microattributions

No microattibutions were provided for United Arab Emirates. Please contact us, if you are willing to review existing information or provide new data.

To provide new epidemiological information and/or report mistakes, please register/log in first or use the Contact Us form.

Important Note: The relative allele frequencies presented in IthaMaps are not calculated by ITHANET, but they are extracted from the corresponding publications. ITHANET is not responsible for any mistakes in the data. Please use this information with caution! We encourage scientists that have more detailed or updated epidemiological information to contact us.

Disclaimer: The information on this website is provided as an information resource only and must not to be used as a substitute for professional diagnosis and treatment. The ITHANET Portal and IthaMaps are not responsible or liable for any advice, course of treatment, diagnosis or any other information, services or products that an individual obtains through this website.

Note: The information you provide for the specific country will appear on the IthaMaps website and your contribution will be acknowledged.

Country:

Contributor's details

To be included in ITHANET Organisations & Experts

Name:		Organisation's name:
Surname:		Organisation's brief description:
Title:		Organisation's address:
Expertise/Research interests:		Organisation's City:
Address:		Organisation's Country:
City:		Organisation's website:
Country:		E-mail:
ORCID

Healthcare Policies

Health-policy	Select one Answer	Comment
Prevention programme
SCD newborn screening
Prenatal screening
Antenatal screening
Haemoglobinopathies patient registry
Rare disease patient registry
Dedicated treatment centres
Blood transfusion availability
Iron chelation availability
MRI facilities
Patient associations
Genetic counselling

Status of major Haemoglobinopathies

In Expected Incidence of β-thalassaemia and sickle cell disease please provide the number of expected affected births/year (without prevention).
In Incidence of β-thalassaemia and sickle cell disease please provide the number of affected births/year (after prevention).

Haemoglobinopathy	Provide value		Comment
Prevalence of β-thalassaemia carriers		% of the population
Prevalence of sickle cell disease carriers		% of the population
Prevalence of α-thalassaemia carriers		% of the population
Prevalence of Hb E carriers		% of the population
Prevalence of Hb C carriers		% of the population
Expected incidence of β-thalassaemia		expected affected births/year
Expected incidence of sickle cell disease		expected affected births/year
Expected incidence of α-thalassaemia		expected affected births/year
Incidence of β-thalassaemia		affected births/year
Incidence of sickle cell disease		affected births/year
Incidence of α-thalassaemia		affected births/year
Known β-thalassaemia patients		patients
Known sickle cell disease patients		patients

Mutation Frequencies

Please provide details about publications reporting mutation frequencies in the country of reference (either country-wide studies or region-specific studies).

Show on map:		Information to display:
Minimum sample size: